ArticleJournal of radiation research2019
Mechanism and therapeutic window of a genistein nanosuspension to protect against hematopoietic-acute radiation syndrome.
Article in Journal of radiation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Multiphasic blood transcriptomic signatures of radioprotection by BIO 300, a synthetic genistein nanosuspension, in a nonhuman primate model of acute radiation syndrome.Journal of translational medicine · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- E0703 targets ERβ to facilitate the upregulation of GLI3, thereby alleviating irradiation-induced DNA damage on lymphocytes.Cellular & molecular biology letters · 2025Article
- The Genistein Supply and Elemental Composition of Rat Kidneys in an Induced Breast Cancer Model.Nutrients · 2025Article
- Adjuvant Anti-tumor Therapy with Polyphenolic Compounds: A Review.Current medicinal chemistry · 2025Review
- Impact of dietary ingredients on radioprotection and radiosensitization: a comprehensive review.Annals of medicine · 2024Review
- BIO 300 Attenuates Whole Blood Transcriptome Changes in Mice Exposed to Total-Body Radiation.International journal of molecular sciences · 2024Article
- A Novel TGFβ Receptor Inhibitor, IPW-5371, Prevents Diet-induced Hepatic Steatosis and Insulin Resistance in Irradiated Mice.Radiation research · 2024Article
- Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives.Current pharmaceutical biotechnology · 2024Review
- Genistein: a promising modulator of apoptosis and survival signaling in cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Feasibility of Reducing Animal Numbers in Radiation Countermeasure Experiments from Historic Levels when using Sample Size Calculations.Radiation research · 2023Review
- The radioprotectant nano-genistein enhances radiotherapy efficacy of lung tumors in mice.Translational lung cancer research · 2023Article
- Nanodrugs with intrinsic radioprotective exertion: Turning the double-edged sword into a single-edged knife.Exploration (Beijing, China) · 2023Review
- The delayed effects of acute radiation exposure (DEARE): characteristics, mechanisms, animal models, and promising medical countermeasures.International journal of radiation biology · 2023Review
- Establishing a Murine Model of the Hematopoietic Acute Radiation Syndrome.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Inter-agency perspective: Translating advances in biomarker discovery and medical countermeasures development between terrestrial and space radiation environments.Life sciences in space research · 2022Article
- Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates.Scientific reports · 2022Article
- A "Failed" Assay Development for the Discovery of Rescuing Small Molecules from the Radiation Damage.SLAS discovery : advancing life sciences R & D · 2021Article
- Microbiome study in irradiated mice treated with BIO 300, a promising radiation countermeasure.Animal microbiome · 2021Article
- Could Polyphenols Really Be a Good Radioprotective Strategy?Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
There are no FDA-approved drugs that can be administered prior to ionizing radiation exposure to prevent hematopoietic-acute radiation syndrome (H-ARS). A suspension of synthetic genistein nanoparticles was previously shown to be an effective radioprotectant against H-ARS when administered prior to exposure to a lethal dose of total body radiation. Here we aimed to determine the time to protection and the duration of protection when the genistein nanosuspension was administered by intramuscular injection, and we also investigated the drug's mechanism of action. A single intramuscular injection of the genistein nanosuspension was an effective radioprotectant when given prophylactically 48 h to 12 h before irradiation, with maximum effectiveness occurring when administered 24 h before. No survival advantage was observed in animals administered only a single dose of drug after irradiation. The dose reduction factor of the genistein nanosuspension was determined by comparing the survival of treated and untreated animals following different doses of total body irradiation. As genistein is a selective estrogen receptor beta agonist, we also explored whether this was a central component of its radioprotective mechanism of action. Mice that received an intramuscular injection of an estrogen receptor antagonist (ICI 182,780) prior to administration of the genistein nanosuspension had significantly lower survival following total body irradiation compared with animals only receiving the nanosuspension (P < 0.01). These data define the time to and duration of radioprotection following a single intramuscular injection of the genistein nanosuspension and identify its likely mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.